The safety and efficacy of NeVa mechanical thrombectomy device in acute ischemic stroke: A systematic review and meta-analysis

• Published in: Journal of clinical neuroscience Vol. 130; p. 110892
• Main Authors: Habibi, Mohammad Amin, Mirjnani, Mohammad Sina, Kargar-Soleimanabad, Saeed, Akbari Javar, Mohammad Taha, Diyanati, Maryam, Ahmadvand, Muhammad Hussain, Berglar, Inka K., Dmytriw, Adam A.
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01-12-2024
• Subjects: Ischemia; Mechanical Thrombectomy; Neva; Stroke; Mechanical Thrombectomy; Stroke; Ischemia; Neva
• ISSN: 0967-5868; 1532-2653; 1532-2653
• DOI: 10.1016/j.jocn.2024.110892

•This study focused on acute ischemic stroke.•This study highlights the clinical benefits of NeVa Mechanical Thrombectomy Device as a viable option for acute ischemic stroke.•The complete arterial recanalization rate was 0.76 [95%CI: 0.49–1.04].•The overall recanalization rate was found to be 0.97 [95%CI: 0.94–1.00].
Recent favorable cohort studies on endovascular therapy for ischemic stroke have predominantly utilized NeVa thrombectomy (NeVaTM) stent retrievers. We carried out a systematic review and meta-analysis to investigate the efficacy and safety of this second-generation stent retriever in acute ischemic stroke patients.
We conducted the study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The electronic databases of PubMed, Embase, and Scopus were searched until 26 November 2023 and was updated on August 1, 2024.
This meta-analysis systematically investigated 11 studies with a total of 805 patients suffering from ischemic stroke. The mean age of participants across the studies ranged from 65 to 77 years with a male preponderance of 50.16 %. While ten studies reported on the etiology of strokes, some studies reported the risk factors such as hypertension, dyslipidemia, diabetes, history of coronary artery disease, and previous stroke. The results of our study indicate that the all-hemorrhagic complications rate was 0.32 (95 %CI: 0.18–0.45), while the complete arterial recanalization rate was 0.76 [95 %CI: 0.49–1.04]. The overall recanalization rate was found to be 0.97 [95 %CI: 0.94–1.00]. Moreover, the postoperative hemorrhage rate was 0.28 [95 %CI: 0.14–0.41], while the repeated re-thrombosis rate was 0.01 [95 %CI: −0.01–0.03]. Lastly, the vasospasm rate was calculated to be 0.09 [95 %CI: −0.03–0.21].
NeVa™ is a safe option capable of achieving a high rate of recanalization and functional independence.
Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, International Prospective Register of Systematic Reviews; NeVa™, NeVa Thrombectomy; ICH, Intracranial Hemorrhage; mTICI, modified Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale; ACA, Anterior Cerebral Artery; MCA, Middle Cerebral Artery; PCA, Posterior Cerebral Artery; ICA, Internal Carotid Artery; NIHSS, National Institutes of Health Stroke Scale.